Lunit Inc. (328130)
KRX SM KRX SM Primary Summary
328130 Chart
Lunit Inc. (328130) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lunit Inc. ever had a stock split?
Lunit Inc. Profile
| Insurance Industry | Financials Sector | - CEO | KRX SM Exchange | KR7328130000 ISIN |
| South Korea Country | 307 Employees | - Last Dividend | 4 May 2026 Last Split | - IPO Date |
Overview
Lunit Inc., founded in 2013 and headquartered in Seoul, South Korea, specializes in advancing AI-based software solutions aimed at enhancing cancer detection, diagnosis, and treatment processes. By leveraging cutting-edge artificial intelligence, Lunit Inc. is at the forefront of transforming medical imaging and pathology with solutions designed to assist healthcare professionals in making more accurate and efficient clinical decisions. The company's innovative approach to integrating AI into healthcare practices marks a significant step forward in the fight against cancer, ensuring patients receive timely and effective care.
Products and Services
- AI Solution for Chest X-ray:
- AI Solution for Mammography:
- AI-powered Biomarker for Immune Phenotyping:
- PD-L1 Quantification for Immunotherapy:
This product utilizes artificial intelligence to analyze chest X-rays for the detection of pulmonary anomalies, including nodules and other indicators of lung cancer. By enhancing the accuracy and speed of diagnosis, it supports radiologists in identifying potential issues early, leading to improved patient outcomes.
Lunit Inc.'s AI solution for mammography applies advanced algorithms to assist in the screening and diagnosis of breast cancer from mammograms. Its high precision in identifying potential malignant lesions helps in reducing false positives and negatives, thereby optimizing the screening process and early cancer detection.
This innovative solution offers an AI-powered biomarker analysis for immune cell phenotyping, facilitating a deeper understanding of the tumor microenvironment. It helps in identifying the immune response within the cancer tissue, which can be crucial for developing personalized cancer treatments and immunotherapy approaches.
Quantifying PD-L1 expression levels through AI algorithms allows for more precise assessment of a patient's eligibility for immunotherapy. This product underscores the importance of tailored treatments in cancer care by providing insights into the likelihood of a patient responding to PD-L1 inhibitor therapies.
